mRNA flu investigational
Selected indexed studies
- Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years: A Randomized Clinical Trial. (JAMA, 2025) [PMID:40332892]
- Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial. (J Infect Dis, 2025) [PMID:38934845]
- An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers. (Hum Vaccin Immunother, 2025) [PMID:40174609]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years: A Randomized Clinical Trial. (2025) pubmed
- Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial. (2025) pubmed
- An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers. (2025) pubmed
- Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study. (2026) pubmed
- Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50-75 years: a phase 1/2, open-label, randomised trial. (2025) pubmed
- Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults. (2026) pubmed
- Influenza chemotherapy: a review of the present state of art and of new drugs in development. (2000) pubmed
- Risk of Worsening Heart Failure and All-Cause Mortality Following COVID-19 Vaccination in Patients With Heart Failure: A Nationwide Real-World Safety Study. (2023) pubmed
- BNT162b2 mRNA Vaccination Against Coronavirus Disease 2019 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5-18 Years-United States, July 2021 - April 2022. (2023) pubmed
- Transcriptional signatures of influenza A/H1N1-specific IgG memory-like B cell response in older individuals. (2016) pubmed